Secretion of GIP in responders to acarbose in obese Type 2(NIDDM) patients

Izumi Takei, Kazunori Miyamoto, Osamu Funae, Norimi Ohashi, Syu Meguro, Mikiya Tokui, Takao Saruta

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)


Acarbose has been shown to reduce postprandial hyperglycemia and to improve lipid parameters in diabetics via its inhibitory effects on intestinal α-glucosidases. Response to acarbose may therefore be dependent upon gastric or pancreatic hormone function. To test this hypothesis, we treated 27 mild type 2 (NIDDM) Japanese diabetics who were mildly obese with low-dose acarbose (150 mg/day) for 3 months. We then performed a responder analysis to determine specific hormonal responses that may be associated with a good response to acarbose. At the end of the treatment period, a total of 15 evaluable patients was grouped as responders (n=6) and nonresponders (n=9) based on an effective decrease in postprandial glucose levels (>30 mg/day) and glycosylated hemoglobin (HbA1c) levels (>0.5%). There were no differences between the two groups in demographic variables or mean postprandial glucose levels at baseline. There was a small but significant increase in postprandial cholecystokinin (CCK) in responders, and fasting gastric inhibitory peptide (GIP) levels were significantly increased in responders and all patients after treatment. Serum leptin levels were reduced by treatment in our mildly obese responders and this was associated with a significant decrease in body weight. These results suggest that treatment with low-dose acarbose may reduce hyperglycemia in mild type 2 Japanese patients and may improve metabolic control by regulating hormones involved in glycemic control and digestive absorption. Acarbose may provide a safe adjunct to help treat insulin resistance in type 2 patients.

Original languageEnglish
Pages (from-to)245-249
Number of pages5
JournalJournal of Diabetes and its Complications
Issue number5
Publication statusPublished - 2001 Aug 29


  • Acarbose
  • GIP
  • Leptin
  • Obesity
  • Type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'Secretion of GIP in responders to acarbose in obese Type 2(NIDDM) patients'. Together they form a unique fingerprint.

Cite this